Search papers, labs, and topics across Lattice.
1
0
0
10
Dual-target CD19/CD22 CAR-T-cell therapy, especially when combined with ASCT, demonstrates sustained clinical benefit and may overcome the negative prognostic impact of TP53 alterations in relapsed/refractory aggressive B-NHL.